JP2015508099A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508099A5 JP2015508099A5 JP2014558733A JP2014558733A JP2015508099A5 JP 2015508099 A5 JP2015508099 A5 JP 2015508099A5 JP 2014558733 A JP2014558733 A JP 2014558733A JP 2014558733 A JP2014558733 A JP 2014558733A JP 2015508099 A5 JP2015508099 A5 JP 2015508099A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- conr
- conditions
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261601101P | 2012-02-21 | 2012-02-21 | |
| US61/601,101 | 2012-02-21 | ||
| PCT/US2012/070252 WO2013126132A1 (en) | 2012-02-21 | 2012-12-18 | Cyclic diaminopyrimidine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508099A JP2015508099A (ja) | 2015-03-16 |
| JP2015508099A5 true JP2015508099A5 (enExample) | 2016-12-08 |
| JP6059260B2 JP6059260B2 (ja) | 2017-01-11 |
Family
ID=47459190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558733A Expired - Fee Related JP6059260B2 (ja) | 2012-02-21 | 2012-12-18 | 環状ジアミノピリジン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9073944B2 (enExample) |
| EP (1) | EP2817306B1 (enExample) |
| JP (1) | JP6059260B2 (enExample) |
| CN (1) | CN104254531B (enExample) |
| AR (1) | AR090103A1 (enExample) |
| AU (1) | AU2012370450B2 (enExample) |
| CA (1) | CA2865040C (enExample) |
| ES (1) | ES2552518T3 (enExample) |
| IL (1) | IL233986A (enExample) |
| WO (1) | WO2013126132A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2955612C (en) | 2014-07-18 | 2022-05-17 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
| AU2017382405B2 (en) | 2016-12-22 | 2021-12-16 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| KR20220153582A (ko) * | 2020-02-14 | 2022-11-18 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 마크로시클릭 ulk1/2 억제제 |
| AU2021357717A1 (en) * | 2020-10-05 | 2023-06-08 | Merck Patent Gmbh | Lmp7-selective inhibitors for the treatment of blood disorders and solid tumors |
| JP7556310B2 (ja) * | 2021-02-26 | 2024-09-26 | スズキ株式会社 | 電動車両 |
| KR20240021751A (ko) | 2021-03-27 | 2024-02-19 | 티알엑스 바이오사이언시스 리미티드 | 치료제의 생체 이용률이 향상된 조성물 |
| US20250000859A1 (en) | 2021-08-25 | 2025-01-02 | Alesta Therapeutics BV | Use of gcn2 inhibitors in treating cancer |
| JP2025509680A (ja) * | 2022-03-14 | 2025-04-11 | ティーアールエックス バイオサイエンシズ リミテッド | 治療薬のバイオアベイラビリティを改善した組成物およびその使用 |
| TW202404979A (zh) * | 2022-07-18 | 2024-02-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抑制並誘導ｅｇｆｒ降解的大環類化合物、其製備方法及其在醫藥上的應用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| SK285141B6 (sk) | 1996-02-13 | 2006-07-07 | Astrazeneca Uk Limited | Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje |
| ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| MXPA02011770A (es) | 2000-05-31 | 2003-04-10 | Astrazeneca Ab | Derivados de indol con actividad de dano vascular. |
| US20050277627A1 (en) | 2000-07-07 | 2005-12-15 | Arnould Jean C | Colchinol derivatives as vascular damaging agents |
| KR20030022264A (ko) | 2000-07-07 | 2003-03-15 | 앤지오젠 파마슈티칼스 리미티드 | 신생 혈관 형성 억제제인 콜치놀 유도체 |
| ZA200501536B (en) * | 2002-08-14 | 2006-10-25 | Vertex Pharma | Protein kinase inhibitors and uses thereof |
| BRPI0413005A (pt) * | 2003-07-29 | 2006-09-26 | Irm Llc | compostos e composições como inibidores da proteìna cinase |
| NZ545270A (en) * | 2003-07-30 | 2010-04-30 | Rigel Pharmaceuticals Inc | 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| GB0321710D0 (en) * | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
| CA2631875A1 (en) | 2005-12-06 | 2007-10-04 | Rigel Pharmaceuticals, Inc. | Formulation of insoluble small molecule therapeutics in lipid-based carriers |
| DK1984357T3 (da) * | 2006-02-17 | 2014-01-13 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiaminforbindelser til behandling eller forebyggelse af autoimmunsygdomme |
| US8163902B2 (en) * | 2006-11-21 | 2012-04-24 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| EA201100450A1 (ru) | 2008-09-08 | 2011-10-31 | Мерк Патент Гмбх | Макроциклические пирамидины в качестве ингибиторов протеинкиназы |
-
2012
- 2012-12-18 WO PCT/US2012/070252 patent/WO2013126132A1/en not_active Ceased
- 2012-12-18 ES ES12808646.9T patent/ES2552518T3/es active Active
- 2012-12-18 US US14/379,625 patent/US9073944B2/en active Active
- 2012-12-18 JP JP2014558733A patent/JP6059260B2/ja not_active Expired - Fee Related
- 2012-12-18 EP EP12808646.9A patent/EP2817306B1/en active Active
- 2012-12-18 AU AU2012370450A patent/AU2012370450B2/en not_active Ceased
- 2012-12-18 CA CA2865040A patent/CA2865040C/en active Active
- 2012-12-18 CN CN201280070330.7A patent/CN104254531B/zh not_active Expired - Fee Related
-
2013
- 2013-02-21 AR ARP130100516 patent/AR090103A1/es unknown
-
2014
- 2014-08-06 IL IL233986A patent/IL233986A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015508099A5 (enExample) | ||
| JP2015529657A5 (enExample) | ||
| JP2015509512A5 (enExample) | ||
| ES2927777T3 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP | |
| US9783513B2 (en) | STAT3 inhibitors and their anticancer use | |
| JP2015508086A5 (enExample) | ||
| JP2015535831A5 (enExample) | ||
| JP2014513729A5 (enExample) | ||
| JP2012507522A5 (enExample) | ||
| JP2015508085A5 (enExample) | ||
| ES2755424T3 (es) | Análogos de salinomicina que contienen nitrógeno, síntesis y utilización contra células troncales cancerosas y paludismo | |
| JP2012072150A5 (enExample) | ||
| ES2989922T3 (es) | Compuestos de carborano y métodos de uso de los mismos | |
| RU2013148146A (ru) | Производные адамантила | |
| CN111727042A (zh) | 微管蛋白抑制剂 | |
| JP2014517051A (ja) | ジュウテリウム富化４−ヒドロキシ−５−メトキシ−ｎ，１−ジメチル−２−オキソ−ｎ−［（４−トリフルオロ−メチル）フェニル］−１，２−ジヒドロキノリン−３−カルボキサミド | |
| JP2020002165A (ja) | ジピコリルアミン誘導体及びそれらの薬学的使用 | |
| US9340501B2 (en) | Marinopyrrole derivatives as anticancer agents | |
| WO2023086365A1 (en) | Compositions comprising amino lipid compounds and methods of making and use thereof | |
| JPWO2020102576A5 (enExample) | ||
| AU2019393785A2 (en) | Carborane compounds, carborane analogs, and methods of use thereof | |
| US8871983B2 (en) | Lipid compounds for suppression of tumorigenesis | |
| JPWO2020102100A5 (enExample) | ||
| WO2019102054A1 (es) | Análogos no glicosídicos de alfa-galactosilceramida como activadores de células nkt | |
| JPWO2023121971A5 (enExample) |